ライフサイエンスコーパス: Fcgamma receptor

1 s to fragment cystallizable gamma receptors (Fcgamma receptors).

2 the affinity of the antibody for activating Fcgamma receptors.

3 med at eliciting NAbs that activate specific Fcgamma receptors.

4 derstanding the interaction between IgG4 and Fcgamma receptors.

5 o-acid substitutions that promote binding to Fcgamma receptors.

6 rent affinities between antibodies and their Fcgamma receptors.

7 due to reduced expression of membrane-bound Fcgamma receptors.

8 This indicated involvement of the Fcgamma receptors.

9 dified constant region that does not bind to Fcgamma receptors.

10 alpha (TNF-alpha) and lowered expression of Fcgamma receptors.

11 no major impact on binding to the classical Fcgamma receptors.

12 amma-chain, the common subunit of activating Fcgamma receptors.

13 ller than those observed in the low affinity Fcgamma receptors.

14 ver the antigenic cassette to the activating Fcgamma receptors.

15 ocytes and by PBMC in a reaction mediated by Fcgamma receptors.

16 ot express detectable levels of cell surface Fcgamma receptors.

17 gion that lacks the ability to interact with Fcgamma receptors.

18 fector function or elimination of binding to Fcgamma receptors.

19 known to modulate the effector functions of Fcgamma receptors.

20 have significantly lower binding affinity to Fcgamma receptors.

21 iated through immunoglobulin G engagement of Fcgamma receptors.

22 f CD45 increased markedly upon engagement of Fcgamma receptors.

23 sting that this phenomenon is not limited to Fcgamma receptors.

24 gered the internalisation and degradation of Fcgamma-receptors.

25 red blood cell (PKLR) gene as well as of the Fcgamma receptor 2A and Fcgamma receptor 2C (FCGR2A, FCG

26 ne as well as of the Fcgamma receptor 2A and Fcgamma receptor 2C (FCGR2A, FCGR2C) and Fcgamma recepto

27 and Fcgamma receptor 2C (FCGR2A, FCGR2C) and Fcgamma receptor 3 (FCGR3) genes using real-time quantit

28 peptide-related sequence A, an allele of the Fcgamma receptor, a polymorphism marker in the beta2-adr

29 Among Fcgamma receptors, a protein kinase C (PKC) phosphorylat

30 Second messengers generated by Fcgamma receptors activated integrins, which formed an a

31 Importantly, we show that Fcgamma receptor activation causes nuclear translocation

32 We report that Fcgamma receptor activation in macrophages enhances lyso

33 ctivated eosinophils depends on adhesion and Fcgamma receptor activation, requires elevated ROS produ

34 eered a series of Fc variants with optimized Fcgamma receptor affinity and specificity.

35 In summary, preventing the activation of Fcgamma receptors alleviates renal hypertrophy, inflamma

36 It has been shown previously that the Fcgamma receptors also do not contribute to such CRP-med

37 iple logistic regressions revealed that both Fcgamma receptor and IL-6 -174 polymorphisms were associ

38 evelopment, inhibition of thrombopoiesis and Fcgamma receptor and other polymorphisms will assume inc

39 ng of how an IgG antibody generally docks on Fcgamma receptor and the requirement of immune complex f

40 correlation between b12 variant affinity for Fcgamma receptor and variant function in antibody-depend

41 ytotoxicity function, and binding ability to Fcgamma receptors and C1q of the test oligospecific anti

42 IgG isotypes can differentially bind to Fcgamma receptors and complement, making the selection o

43 g antibodies can enable viral uptake through Fcgamma receptors and down-regulate signaling cascades i

44 gulated kinase phosphorylation downstream of Fcgamma receptor, and no increased NK-cell apoptosis.

45 ceptor A IgG4 with the neonatal Fc receptor, Fcgamma receptors, and complement-activating C1q by cons

46 the IgG1 subclass, including complexes with Fcgamma receptors, and structures for intact antibodies,

47 Because Fcgamma receptors are implicated in disease susceptibili

48 Upon sialylation, the affinities for Fcgamma receptors are reduced, whereas those for alterna

49 anti-inflammatory effects through activating Fcgamma receptors bearing an immunoreceptor tyrosine-bas

50 ll function and may be broadly applicable to Fcgamma-receptor-bearing cells.

51 ly reduced by blocking any of the following: Fcgamma receptor binding (P = 0.048), eosinophil adhesio

52 body with an engineered Fc region to enhance Fcgamma receptor binding affinity.

53 Fc tail, rendering the antibody incapable of Fcgamma receptor binding and antibody-dependent cellular

54 t in this paper chemoenzymatic synthesis and Fcgamma receptor binding of an array of homogeneous IgG-

55 inguishable from those of palivizumab, their Fcgamma receptor binding profiles were very different, w

56 Comparisons with a variant incapable of Fcgamma receptor binding showed that engagement of these

57 Enhanced Fcgamma receptor binding was associated with reduced vir

58 limination of C1q binding did not compromise Fcgamma-receptor binding or in vitro phagocytosis.

59 sistant antisera was dependent on activating Fcgamma receptors but not complement.

60 d independently of complement receptor 2 and Fcgamma receptors, but was dependent upon B-cell recepto

61 These results provide a mechanism by which Fcgamma receptors can elevate circulating BLyS levels an

62 us-responsive gammadelta T cells express the Fcgamma-receptor CD16, suggesting that gammadelta T cell

63 ow that murine pDC, as well as myDC, express Fcgamma receptors (CD16/CD32) and can use these receptor

64 oated with IgG bound by its Fc domain to the Fcgamma receptor CD16a.

65 High-level expression of the Fcgamma receptor, CD32hi, on CD4+ T cells was associated

66 d mice expressed strikingly higher levels of Fcgamma receptors compared with DCs from adults and were

67 oligomerization with protein G or binding to Fcgamma receptors converted both anti-Fn14 antibodies in

68 cumulation rather than altered expression of Fcgamma receptors, could be mimicked by co-culture of WT

69 We provide evidence that Fcgamma receptor cross-linking triggers a rapid release

70 and rheumatoid arthritis, and following IgG Fcgamma receptor cross-linking.

71 iated cell cytotoxicity reporter assays, and Fcgamma receptor-deficient (Fcer1g(-/-)) mice, we show t

72 Moreover, diabetic Fcgamma receptor-deficient mice had less mesangial matri

73 kidneys and in mesangial cells cultured from Fcgamma receptor-deficient mice.

74 anti-CD47 mAbs also induced phagocytosis by Fcgamma receptor-deficient murine macrophages.

75 Transcriptional pathways for Fcgamma receptor dependent phagocytosis were among share

76 immune complexes in premalignant tissue and Fcgamma receptor-dependent activation of myeloid cells.

77 e large immune complexes was associated with Fcgamma receptor-dependent binding to Kupffer cells in t

78 ficacy of CR9114 against AA60 is mediated by Fcgamma receptor-dependent mechanisms.

79 uently caused by allo- or autoantibodies via Fcgamma receptor-dependent phagocytosis.

80 an IgG1 constant region modified to minimize Fcgamma receptor-dependent platelet destruction (G1Delta

81 g of ehrlichial attachment or complement and Fcgamma-receptor-dependent destruction.

82 as the most abundantly distributed class II Fcgamma receptors, differentially influence Ab-mediated

83 tion of actin cytoskeleton remodeling during Fcgamma receptor-driven phagocytosis.

84 n cytoskeleton remodeling is fundamental for Fcgamma receptor-driven phagocytosis.

85 duced by the activation of the Vav-dependent Fcgamma receptor-elicited NADPH oxidase activity.

86 of Rac recruited to the phagosomes formed by Fcgamma receptor engagement and thus is able to regulate

87 vivo half-lives by a mechanism that requires Fcgamma receptor engagement in a humanized mouse model.

88 recruited to the early phagosomes formed via Fcgamma receptor engagement.

89 and tested the consequences of multi-valent Fcgamma-receptor engagement in in vitro and in vivo syst

90 he ability to bind beta-glucan and signal at Fcgamma receptors enhance defense against Pneumocystis f

91 ion also decreased expression of stimulatory Fcgamma receptors, especially FcgammaRIII, and strongly

92 vaccinal effect is mediated by engagement of Fcgamma receptors expressed on antigen-presenting cells.

93 The low-affinity Fcgamma receptors, expressed on immune cells, are import

94 ll depletion is dependent on the presence of Fcgamma receptor-expressing macrophages within the tumor

95 ibution of effector functions mediated by Fc-Fcgamma receptor (Fc-FcgammaR) interactions for optimal

96 -delta in inflammatory responses elicited by Fcgamma receptor (FcgammaR) activation.

97 d anti-CD19 antibody, XmAb5574, has enhanced Fcgamma receptor (FcgammaR) binding affinity, leading to

98 a region overlapping with complement C1q and Fcgamma receptor (FcgammaR) binding sites.

99 Fcgamma receptor (FcgammaR) clustering on monocytes/macr

100 We sought to determine the role of Fcgamma receptor (FcgammaR) IIa in IVIg-induced anaphyla

101 We determined whether polymorphisms in Fcgamma receptor (FcgammaR) IIa or FcgammaRIIIa genes we

102 ) binding to neonatal Fc receptor (FcRn) and Fcgamma receptor (FcgammaR) is important for evaluating

103 ferentiation protein (MyD88) pathway and the Fcgamma receptor (FcgammaR) pathway in the induction of

104 CR3, the scavenger receptor A (SRA), and the Fcgamma receptor (FcgammaR), respectively.

105 , leads to the upregulation of an inhibitory Fcgamma receptor (FcgammaR), thereby protecting against

106 One strategy involves encoding a decoy Fcgamma receptor (FcgammaR), which blocks Fc-mediated ef

107 We report here that humanized, non-Fcgamma receptor (FcgammaR)-binding monoclonal antibodie

108 We show that Fcgamma receptor (FcgammaR)-mediated activation of human

109 Consequently, in the absence of FcRn, Fcgamma receptor (FcgammaR)-mediated antigen uptake fail

110 Fcgamma receptor (FcgammaR)-mediated entry of infectious

111 cytoskeleton is dynamically remodeled during Fcgamma receptor (FcgammaR)-mediated phagocytosis in a p

112 including interferon and JAK-STAT signaling, Fcgamma receptor (FcgammaR)-mediated phagocytosis, and a

113 All seven mAbs activated Fcgamma receptor (FcgammaR)-mediated signalling pathways

114 ADE has attributed enhanced pathogenesis to Fcgamma receptor (FcgammaR)-mediated viral entry, rather

115 d neutralization activity required competent Fcgamma receptor (FcgammaR).

116 ay without any concomitant engagement of the Fcgamma receptor (FcgammaR).

117 uires AQP4-bound IgG to engage an astrocytic Fcgamma receptor (FcgammaR).

118 body and its interaction with the inhibitory Fcgamma receptor (FcgammaR)IIB.

119 ily were found to interact with cell-surface Fcgamma receptors (FcgammaR) and activate leukocyte-medi

120 ported by innate immune molecules, including Fcgamma receptors (FcgammaR) and complement.

121 they fail to protect mice lacking activating Fcgamma receptors (FcgammaR) and the complement opsonin

122 ultiplex assay to model the cross-linking of Fcgamma receptors (FcgammaR) by Abs, which is required t

123 ed by TA-targeted mAb, only polymorphisms of Fcgamma receptors (FcgammaR) expressed by patients' lymp

124 nding of the Fcgamma regions to low-affinity Fcgamma receptors (FcgammaR) expressed on effector cells

125 Targeting antigens (Ag) to Fcgamma receptors (FcgammaR) intranasally (i.n.) enhance

126 b Fc region to effectively engage activating Fcgamma receptors (FCgammaR) is essential for antibody e

127 ith C5a failed to modulate the expression of Fcgamma receptors (FcgammaR) or to otherwise alter the a

128 Fcgamma receptors (FcgammaR) provide important immunoreg

129 pecifically neutralizes alpha5 and binds the Fcgamma receptors (FcgammaR) with enhanced affinity.

130 However, SAP and CRP bind the same Fcgamma receptors (FcgammaR) with similar affinities, an

131 phils express both activating and inhibitory Fcgamma receptors (FcgammaR), and their relative express

132 teraction between the anti-TNF Fc-region and Fcgamma receptors (FcgammaR), and whether the absence of

133 ut also accessory cells that bear activating Fcgamma receptors (FcgammaR), providing additional T-cel

134 ression of inhibitory rather than activating Fcgamma receptors (FcgammaR), thereby limiting the effic

135 events phagocytosis mediated by integrin and Fcgamma receptors (FcgammaR), whereas the genetic deleti

136 Fcgamma receptors (FcgammaR)-mediated crosslinking incre

137 ol the mobility and clustering of phagocytic Fcgamma receptors (FcgammaR).

138 therapy, where they engage target cells via Fcgamma receptors (FcgammaR).

139 tic cells and nucleoprotein autoantigens and Fcgamma receptors (FcgammaR).

140 ated by phagocytosis and by cross-linking of Fcgamma receptors (FcgammaR).

141 We show that Fcgamma-receptor (FcgammaR) antigen targeting facilitate

142 omeningitis virus (LCMV) suppressed multiple Fcgamma-receptor (FcgammaR) functions.

143 While engagement of the inhibitory Fcgamma-receptor (FcgammaR) IIB is an absolute requireme

144 itis virus (LCMV) exhibit a severe defect in Fcgamma-receptor (FcgammaR)-mediated antibody effector f

145 t neutrophil up-regulation of the inhibitory Fcgamma receptor (FcgammaR2b).

146 ne complexes, cDNAs for the four major human Fcgamma receptors (FcgammaRI, FcgammaRIIa, FcgammaRIIb,

147 dies for selective binding to the activating Fcgamma receptor FcgammaRIIa results in enhanced ability

148 An unexpected requirement for inhibitory Fcgamma receptor FcgammaRIIB coengagement has recently b

149 clonal antibodies (mAbs) with the inhibitory Fcgamma receptor FcgammaRIIB is required for immune acti

150 TP) involves up-regulation of the inhibitory Fcgamma receptor (FcgammaRIIB) in splenic macrophages.

151 aneously engage both CD20 and the inhibitory Fcgamma receptor, FcgammaRIIb, in a bipolar configuratio

152 rement for the coengagement of an inhibitory Fcgamma receptor, FcgammaRIIB.

153 fect on the affinity of Fc to the inhibitory Fcgamma receptor, FcgammaRIIb.

154 Gs enhanced interactions with the activating Fcgamma receptor FcgammaRIIIa; when incorporated into im

155 We revealed that distinct Fcgamma receptor (FcgammaRs) dependency and mechanisms a

156 f antibodies is dependent on engagement with Fcgamma receptors (FcgammaRs) and activation of the asso

157 ment activation and binding to all classical Fcgamma receptors (FcgammaRs) and to C1q while binding t

158 Fcgamma receptors (FcgammaRs) are key immune receptors r

159 ivation fragment, the anaphylatoxin C5a, and Fcgamma receptors (FcgammaRs) been defined.

160 Fcgamma receptors (FcgammaRs) bind IgG-opsonized particl

161 Fcgamma receptors (FcgammaRs) classically modulate intra

162 In contrast, deficiency of Fcgamma receptors (FcgammaRs) did not affect the product

163 city, whereas the constant Fc domain engages Fcgamma receptors (FcgammaRs) expressed on the surface o

164 he Fc domain interacts with diverse types of Fcgamma receptors (FcgammaRs) expressed on the surface o

165 Fcgamma receptors (FcgammaRs) for IgG couple innate and

166 Four murine Fcgamma receptors (FcgammaRs) have been identified at pr

167 e of immune complexes (ICs) via low-affinity Fcgamma receptors (FcgammaRs) on dendritic cells (DCs) i

168 agement of the Fc segment of antibodies with Fcgamma receptors (FcgammaRs) on immune cells upon bindi

169 n positions Fcs to activate pro-inflammatory Fcgamma receptors (FcgammaRs) on immune cells.

170 heir targets may vary, their engagement with Fcgamma receptors (FcgammaRs) on numerous immune effecto

171 of the individual activating and inhibitory Fcgamma receptors (FcgammaRs) on splenic DC subsets in v

172 Fcgamma receptors (FcgammaRs) play critical roles in hum

173 neutralizing antibody IgG1 b12 and cellular Fcgamma receptors (FcgammaRs) plays an important role in

174 main of an antibody for increased binding to Fcgamma receptors (FcgammaRs) significantly enhanced Fc-

175 Low affinity-activating Fcgamma receptors (FcgammaRs) that bind immune complexes

176 cell-surface immunoglobulin receptors (i.e. Fcgamma receptors (FcgammaRs)) on RAW 264.7 macrophages,

177 s translated into cellular responses through Fcgamma receptors (FcgammaRs), a structurally and functi

178 ned antigen-specific antibody recruitment of Fcgamma receptors (FcgammaRs), antibody-dependent cellul

179 immunoprophylaxis treatment in mice lacking Fcgamma receptors (FcgammaRs), complement (C3), both, or

180 specific interactions with distinct types of Fcgamma receptors (FcgammaRs), the Fc domain of immunogl

181 ctor functions of antibodies are mediated by Fcgamma receptors (FcgammaRs), which are found on most i

182 ncluding the neonatal Fc receptor (FcRn) and Fcgamma receptors (FcgammaRs), which confer pleiotropic

183 l antibody (mAb) binding to the cell-surface Fcgamma receptors (FcgammaRs), which mediate cytotoxic a

184 f the functions of IgGs are mediated through Fcgamma receptors (FcgammaRs), which transduce interacti

185 ic IgG, we investigated the evolution of the Fcgamma receptors (FcgammaRs)-activating capabilities of

186 tibodies that cause thrombocytopenia through Fcgamma receptors (FcgammaRs).

187 gh interaction with activating or inhibitory Fcgamma receptors (FcgammaRs).

188 generation of C5a, and direct engagement of Fcgamma receptors (FcgammaRs).

189 eins are phagocytosed by macrophages through Fcgamma receptors (FcgammaRs).

190 release less IL-1beta after stimulation via Fcgamma receptors (FcgammaRs).

191 plement component C1q or the engagement with Fcgamma receptors (FcgammaRs).

192 mation by activating complement and engaging Fcgamma receptors (FcgammaRs).

193 teracting with human complement proteins and Fcgamma-receptors (FcgammaRs) that are expressed on immu

194 ng bacterial clearance through inhibition of Fcgamma receptor (FcgR)-mediated phagocytosis.

195 the membrane of infected cells and bind the Fcgamma receptor (FcR) of the effector cell population.

196 During Fcgamma receptor (FcR)-mediated phagocytosis by macropha

197 Fcgamma Receptor (FcR)-mediated phagocytosis by macropha

198 the bidirectional transcytosis of IgG by the Fcgamma receptor FcRn.

199 , and characterized for binding to antigens, Fcgamma receptors, FcRn, and C1q.

200 CD4+ T cells that express the high-affinity Fcgamma receptor for IgG (FcgammaRI) in both mouse and h

201 After 15 weeks, the mice lacking Fcgamma receptors had significantly less albuminuria and

202 nes encoding receptors for immunoglobulin G (Fcgamma receptors) have been genetically and functionall

203 erosclerosis via ligation of proinflammatory Fcgamma receptors; however, IgM is unable to ligate Fcga

204 increased neutrophil phagocytic ability and Fcgamma receptor I (CD64) expression.

205 Fcgamma receptor I (FcgammaRI or CD64) is the sole human

206 We determined the role of Fcgamma receptor I (FcgammaRI) and the basis for couplin

207 al reconstruction microscopy, we report that Fcgamma receptor I (FcgammaRI), FcgammaRII, and SIRPalph

208 SAP activates the high-affinity IgG receptor Fcgamma receptor I (FcgammaRI; CD64) and the lectin rece

209 n of complement receptors 1 and 3 as well as FCgamma receptor I on neutrophils and, consequently, inc

210 arker CD68, macrophage scavenger receptor A, Fcgamma receptors I (CD64) and II (CD32); and also immun

211 plasmacytoid dendritic cell (DC) activation, Fcgamma receptor II (FcgammaRII), endocytosis, or nuclea

212 To test this hypothesis, we expressed the Fcgamma receptor IIA (FcgammaR) in A549 lung epithelial

213 e demonstrated a central role for the immune Fcgamma receptor IIa (FcgammaRIIa) in mediating platelet

214 Platelet activation via Fcgamma receptor IIA (FcgammaRIIA) is a critical event i

215 n of coagulation by ICs, is mediated through Fcgamma receptor IIa (FcgammaRIIa); however, the involve

216 tor (TNF), mannose-binding lectin (MBL), and Fcgamma receptor IIa (FCGR2A) as well as clinical factor

217 The CD32a immunoglobulin G (IgG) receptor (Fcgamma receptor IIa) is a potential therapeutic target

218 immunoglobulin G and were attenuated by the Fcgamma receptor IIa-blocking antibody IV.3, suggesting

219 -anti-PGN immune complexes signaling through Fcgamma receptor IIa.

220 B cells expressing the intermediate affinity Fcgamma receptor IIB (CD32B), or coincubation with CD32B

221 Mice lacking the inhibitory Fcgamma receptor IIB (FcgammaRIIB) are protected from CR

222 mice globally deficient in the CRP receptor Fcgamma receptor IIB (FcgammaRIIB) were protected from t

223 rough processes mediated by the IgG receptor Fcgamma receptor IIB (FcgammaRIIB), its immunoreceptor t

224 imulating the upregulation of the inhibitory Fcgamma receptor IIB (FcgammaRIIB).

225 ackground or on a C57BL/6 background lacking Fcgamma receptor IIb (FcgammaRIIb).

226 In contrast, only 1E2 protected Fcgamma receptor IIB knockout (FcgammaRIIB KO) mice and

227 receptor decoy approach using an analogue of Fcgamma receptor IIB; dual blockade of IL-12 and IL-23;

228 sentation, and of the immune complex binding Fcgamma receptor III (CD16).

229 Isoforms of the Fcgamma receptor III (FcgammaRIII or CD16) are cell surf

230 is was characterized by decreased neutrophil Fcgamma receptor III (FcgammaRIII) expression that was o

231 sue of Blood, Yu et al describe a novel anti-Fcgamma receptor III (FcgammaRIII)-albumin fusion protei

232 Fcgamma receptor III (FcgammaRIII; CD16) is a receptor e

233 t, certain acute inflammatory mediators (C5, Fcgamma receptor III, mast cells, and histamine) and ada

234 ctivated NK cells to kill SCCVII cells in an Fcgamma receptor III-dependent manner.

235 ability of bi-TPB-PPB antibodies to bind to Fcgamma receptor IIIa and HER2 oncoprotein on the cell s

236 rther augmented by concomitant activation of Fcgamma receptor IIIa or NK group 2 member D.

237 showed significantly enhanced binding to the Fcgamma receptor IIIa, irrespective of whether plant or

238 rupted the binding between the IgG(1) Fc and Fcgamma receptor IIIa, resulting in decreased ADCC activ

239 the fragment crystallizable [Fc] domain and Fcgamma receptor IIIalpha, respectively) are required fo

240 Deletion of Fcgamma receptor IIIB, associated with systemic lupus er

241 in the downstream signaling pathways for the Fcgamma receptor in monocytes, the Fcepsilon receptor in

242 8I) purified from HEK293T cells bound to all Fcgamma receptors in a manner similar to that of clinica

243 ssected the role of the different neutrophil Fcgamma receptors in the response to therapeutic anti-CD

244 as revealed a critical yet variable role for Fcgamma receptors in their efficacy.

245 inding of Fc to FcgammaRIIIa, the activating Fcgamma receptor, independent of Fc core-fucosylation.

246 ngly, immunocytokine antigen specificity and Fcgamma receptor interactions did not seem necessary for

247 macrophages, indicating a requirement for Fc-Fcgamma receptor interactions.

248 mutant Abs have normal thermal stability and Fcgamma receptor interactions.

249 that YopO specifically blocks Rac-dependent Fcgamma receptor internalization pathway but not complem

250 Consistent with Fcgamma receptor involvement, antibody in nonimmune huma

251 nlike evasion of T cell immunity, this viral Fcgamma receptor is not required to overcome anti-CMV im

252 mouse models, the identification of another Fcgamma receptor is particularly noteworthy.

253 e mechanism by which TLR1/2 ligand increased Fcgamma receptor IV expression on macrophages, leading t

254 ficacy depended on CD4 T cells, CD8 T cells, Fcgamma receptor IV, and macrophages.

255 ted bone marrow-derived dendritic cells from Fcgamma receptor knockout mice inhibited AHR, suggesting

256 n response to stimulation with CX3CL1 or via Fcgamma receptor ligation were severely reduced in Hck(-

257 ng immunity and its mode of action relies on Fcgamma receptor-mediated effector mechanisms, most like

258 , suggesting IVIg's action was not caused by Fcgamma receptor-mediated events.

259 tions that can restore either complement- or Fcgamma receptor-mediated functions on a protease-resist

260 d viral replication and disease severity via Fcgamma receptor-mediated infection of myeloid cells-a p

261 subclass was selected to reduce the risk of Fcgamma receptor-mediated overactivation of microglia.

262 ve immunization approaches carry the risk of Fcgamma receptor-mediated overactivation of microglial c

263 ration, T cell and neutrophil migration, and Fcgamma receptor-mediated oxidative burst in macrophages

264 T in a macrophage cell line inhibits the IgG Fcgamma receptor-mediated phagocytic ability of THP1 cel

265 localizes to nascent phagocytic cups during Fcgamma receptor-mediated phagocytosis, where it display

266 nstrating a crucial role for this protein in Fcgamma receptor-mediated phagocytosis.

267 acking SLAT show an elevation in the rate of Fcgamma receptor-mediated phagocytosis.

268 ,4,5)-trisphosphate [PI(3,4,5)P(3)] regulate Fcgamma receptor-mediated phagocytosis.

269 Notably, all such reports were limited to Fcgamma receptor-mediated phagocytosis.

270 horiomeningitis infection can interfere with Fcgamma-receptor-mediated effector activities, potential

271 Remarkably, TFEB silencing represses the Fcgamma-receptor-mediated enhancements in degradation an

272 To test this hypothesis, we employed Fcgamma-receptor-mediated phagocytosis and endocytosis,

273 We discuss the impact of Fcgamma-receptor-mediated trogocytosis on the efficacy o

274 specialized form of trogocytosis occurs when Fcgamma receptors on acceptor cells take up and internal

275 le for the interaction of the Fc domain with Fcgamma receptors on effector cells and the clearance of

276 Ab5574) was generated to increase binding to Fcgamma receptors on immune cells and thus increase Fc-m

277 yed on immune effector cells, and binding to Fcgamma receptors on natural killer cells and macrophage

278 rge immune complexes with IL-6 that can bind Fcgamma receptors on phagocytic cells and are rapidly in

279 g integrin wave facilitates the zippering of Fcgamma receptors onto the target and integrates the inf

280 ligands that activate G-proteins as well as Fcgamma-receptor or integrin ligation that activates tyr

281 erum completely protected wild-type, but not Fcgamma-receptor or neonatal Fc-receptor knock-out mice.

282 sonized C albicans was strictly dependent on Fcgamma receptors, protein kinase C (PKC), and reactive

283 utant antibodies (N297Q) that do not bind to Fcgamma receptors provide a level of protection similar

284 mouse FcepsilonRI unexpectedly binds to two Fcgamma receptors, raising concerns regarding numerous s

285 Binding studies using Fcgamma receptors revealed enhanced binding of nonfucosy

286 on resonance [SPR]) and cellularly expressed Fcgamma receptors show decreased (up to 5-fold) and incr

287 phages in vitro, likely due to their role in Fcgamma receptor signal transduction.

288 receptor (BCR)-mediated signaling as well as Fcgamma receptor signaling in monocytes and Fcepsilon re

289 ce with diabetes, suggesting that modulating Fcgamma receptor signaling may be renoprotective in diab

290 s and involves predominantly recognition via Fcgamma receptors, signaling via Syk, PI3K, and protein

291 argeted cells by effector cells that express Fcgamma receptors, thereby allowing malignant cells to e

292 We investigated the contribution of IgG Fcgamma receptors to diabetic renal injury in hyperglyce

293 issue of Immunity, Henault et al. show that Fcgamma-receptor, Toll-like receptor 9, and LC3 conspire

294 Engagement of Fcgamma-receptors triggers a range of downstream signall

295 Formation of these complexes resulted in Fcgamma receptor type I-dependent polarization of macrop

296 By micropatterning IgG, the ligand of Fcgamma receptors, we found that the barrier extended we

297 d for minimal background binding to cellular Fcgamma receptors, we identified the flexible stalk regi

298 ive immune opsonins through engagement of an Fcgamma receptor, which can also enhance Ag uptake and p

299 Percoll gradient and then activated via the Fcgamma receptor with opsonized Staphylococcus aureus af

300 d primarily through a set of closely related Fcgamma receptors with both activating and inhibitory ac